[{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Avoro Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Molecular glues","moa":"Protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Avoro Capital Advisors","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Avoro Capital Advisors"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Cancer Research UK Cancer Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MRT-048","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Cancer Research UK Cancer Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Cancer Research UK Cancer Therapeutics"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MRT-048","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MRT-6160","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Monte Rosa Therapeutics","amount2":2.0499999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Monte Rosa Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"MRT-2359","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"MRT-8102","moa":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"5","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"MRT-6160","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Monte Rosa Therapeutics","amount2":2.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Monte Rosa Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"12","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"}]

Find Clinical Drug Pipeline Developments & Deals by Monte Rosa Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the licensing agreement, Novartis will gain exclusive global rights to develop, manufacture, and commercialize MRT-6160, currently under study for immune-mediated conditions.

                          Brand Name : MRT-6160

                          Molecule Type : Small molecule

                          Upfront Cash : $150.0 million

                          October 28, 2024

                          Lead Product(s) : MRT-6160

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : $2,250.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : MRT-6160 is an orally bioavailable VAV1 degrader, which is being developed for the treatment of eurological autoimmune diseases.

                          Brand Name : MRT-6160

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 19, 2024

                          Lead Product(s) : MRT-6160

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : MRT-2359 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader. Currently,It is being evaluated for the treatment of MYC-driven solid tumors.

                          Brand Name : MRT-2359

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 27, 2024

                          Lead Product(s) : MRT-2359

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The proceeds will fund the development of MRT-6160, an orally bioavailable VAV1 degrader, MRT-8102, as well the utilization of the QuEENTM platform to develop immunology and inflammation targets.

                          Brand Name : MRT-6160

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 16, 2024

                          Lead Product(s) : MRT-6160

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : TD Cowen

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The proceeds will fund the development of MRT-6160, an orally bioavailable VAV1 degrader, MRT-8102, as well the utilization of the QuEENTM platform to develop immunology and inflammation targets.

                          Brand Name : MRT-6160

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 15, 2024

                          Lead Product(s) : MRT-6160

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : TD Cowen

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : MRT-8102 is a first-in-class NEK7-directed molecular glue degrader and NLRP3/IL-1β pathway inhibitor being evaluated for multiple inflammatory diseases, including gout and pericarditis.

                          Brand Name : MRT-8102

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 11, 2024

                          Lead Product(s) : MRT-8102

                          Therapeutic Area : Rheumatology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Monte Rosa intends to use the proceeds towards the advancement of its clinical and late preclinical pipeline, including MRT-2359, its orally bioavailable, GSPT1-directed MGD, MRT-6160, its orally bioavailable VAV1-directed MGD, and its NEK7 program.

                          Brand Name : MRT-2359

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 26, 2023

                          Lead Product(s) : MRT-2359

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : $25.0 million

                          Deal Type : Public Offering

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The collaboration aims to discover and develop MGDs, small molecule protein degraders, against targets in cancer and neurological diseases previously considered impossible to drug by using Monte Rosa Therapeutics’ highly differentiated QuEENTM discover...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $50.0 million

                          October 17, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : $2,050.0 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : MRT-2359 is a orally bioavailable investigational molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 pro...

                          Brand Name : MRT-2359

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 17, 2023

                          Lead Product(s) : MRT-2359

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : MRT-6160 is a potent, highly selective, and orally bioavailable degrader of VAV1, which has shown deep degradation of its target with no detectable effects on other proteins.

                          Brand Name : MRT-6160

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 23, 2023

                          Lead Product(s) : MRT-6160

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank